Loading...

Wave Life Sciences

Nasdaq:WVE
Snowflake Description

Flawless balance sheet with reasonable growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
WVE
Nasdaq
$829M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces of novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. The last earnings update was 14 days ago. More info.


Add to Portfolio Compare Print
  • Wave Life Sciences has significant price volatility in the past 3 months.
WVE Share Price and Events
7 Day Returns
-7.7%
NasdaqGM:WVE
1.1%
US Pharmaceuticals
0.2%
US Market
1 Year Returns
-46.1%
NasdaqGM:WVE
9.6%
US Pharmaceuticals
2.9%
US Market
WVE Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Wave Life Sciences (WVE) -7.7% -9.4% -35.7% -46.1% 55.8% -
US Pharmaceuticals 1.1% 2.5% -1.2% 9.6% 9.5% 18.2%
US Market 0.2% -1.6% 2.4% 2.9% 36.1% 41%
1 Year Return vs Industry and Market
  • WVE underperformed the Pharmaceuticals industry which returned 9.6% over the past year.
  • WVE underperformed the Market in United States of America which returned 2.9% over the past year.
Price Volatility
WVE
Industry
5yr Volatility vs Market

WVE Value

 Is Wave Life Sciences undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Wave Life Sciences. This is due to cash flow or dividend data being unavailable. The share price is $24.19.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Wave Life Sciences's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Wave Life Sciences's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGM:WVE PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in USD $-5.16
NasdaqGM:WVE Share Price ** NasdaqGM (2019-05-23) in USD $24.19
United States of America Pharmaceuticals Industry PE Ratio Median Figure of 27 Publicly-Listed Pharmaceuticals Companies 21.05x
United States of America Market PE Ratio Median Figure of 3,085 Publicly-Listed Companies 17.79x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Wave Life Sciences.

NasdaqGM:WVE PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:WVE Share Price ÷ EPS (both in USD)

= 24.19 ÷ -5.16

-4.69x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Wave Life Sciences is loss making, we can't compare its value to the US Pharmaceuticals industry average.
  • Wave Life Sciences is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Wave Life Sciences's expected growth come at a high price?
Raw Data
NasdaqGM:WVE PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -4.69x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts
17.3%per year
United States of America Pharmaceuticals Industry PEG Ratio Median Figure of 21 Publicly-Listed Pharmaceuticals Companies 1.67x
United States of America Market PEG Ratio Median Figure of 2,123 Publicly-Listed Companies 1.54x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Wave Life Sciences, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Wave Life Sciences's assets?
Raw Data
NasdaqGM:WVE PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in USD $5.75
NasdaqGM:WVE Share Price * NasdaqGM (2019-05-23) in USD $24.19
United States of America Pharmaceuticals Industry PB Ratio Median Figure of 179 Publicly-Listed Pharmaceuticals Companies 3.23x
United States of America Market PB Ratio Median Figure of 5,201 Publicly-Listed Companies 1.84x
NasdaqGM:WVE PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:WVE Share Price ÷ Book Value per Share (both in USD)

= 24.19 ÷ 5.75

4.21x

* Primary Listing of Wave Life Sciences.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Wave Life Sciences is overvalued based on assets compared to the US Pharmaceuticals industry average.
X
Value checks
We assess Wave Life Sciences's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Wave Life Sciences has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

WVE Future Performance

 How is Wave Life Sciences expected to perform in the next 1 to 3 years based on estimates from 5 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
17.3%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Wave Life Sciences expected to grow at an attractive rate?
  • Wave Life Sciences's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
  • Wave Life Sciences's earnings growth is expected to exceed the United States of America market average.
  • Wave Life Sciences's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqGM:WVE Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGM:WVE Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts 17.3%
NasdaqGM:WVE Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 5 Analysts 54.4%
United States of America Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 14.8%
United States of America Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 5.5%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.7%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGM:WVE Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGM:WVE Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 432 -68 198 3
2022-12-31 180 -86 -150 3
2021-12-31 88 -141 -185 3
2020-12-31 61 -172 -193 5
2019-12-31 65 -149 -144 5
NasdaqGM:WVE Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-03-31 16 -41 -156
2018-12-31 14 -23 -147
2018-09-30 12 -13 -140
2018-06-30 9 -7 -127
2018-03-31 5 -99 -116
2017-12-31 4 -84 -102
2017-09-30 3 -74 -90
2017-06-30 3 -63 -82
2017-03-31 2 -42 -69
2016-12-31 1 -32 -56
2016-09-30 1 -25 -44
2016-06-30 0 -16 -31

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Wave Life Sciences's earnings are expected to grow by 17.3% yearly, however this is not considered high growth (20% yearly).
  • Wave Life Sciences's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGM:WVE Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below

All data from Wave Life Sciences Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:WVE Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 4.05 4.05 4.05 1.00
2022-12-31 -3.38 -2.27 -5.04 3.00
2021-12-31 -5.37 -5.28 -5.45 2.00
2020-12-31 -5.02 -3.86 -5.83 5.00
2019-12-31 -4.23 -1.69 -5.44 5.00
NasdaqGM:WVE Past Financials Data
Date (Data in USD Millions) EPS *
2019-03-31 -5.16
2018-12-31 -5.06
2018-09-30 -4.89
2018-06-30 -4.53
2018-03-31 -4.21
2017-12-31 -3.85
2017-09-30 -3.52
2017-06-30 -3.35
2017-03-31 -2.95
2016-12-31 -2.44
2016-09-30 -2.12
2016-06-30 -1.83

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Wave Life Sciences will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Wave Life Sciences's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Wave Life Sciences has a total score of 4/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

WVE Past Performance

  How has Wave Life Sciences performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Wave Life Sciences's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Wave Life Sciences does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Wave Life Sciences's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Wave Life Sciences's 1-year growth to the US Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
Wave Life Sciences's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Wave Life Sciences Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:WVE Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 16.02 -155.61 42.41
2018-12-31 14.41 -146.65 39.51
2018-09-30 11.70 -139.61 33.64
2018-06-30 8.53 -127.48 31.36
2018-03-31 4.93 -116.13 29.13
2017-12-31 3.89 -101.98 26.98
2017-09-30 3.47 -89.64 25.27
2017-06-30 2.55 -81.68 21.64
2017-03-31 1.87 -68.65 18.63
2016-12-31 1.09 -55.66 15.99
2016-09-30 0.81 -44.05 14.56
2016-06-30 0.42 -31.45 13.47
2016-03-31 0.13 -23.58 11.73
2015-12-31 0.15 -19.20 10.39
2015-09-30 0.15 -13.85 7.70
2015-06-30 0.15 -10.28 5.62
2015-03-31 0.03 -7.64 4.30
2014-12-31 -5.23 3.00
2013-12-31 -7.96 3.97

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Wave Life Sciences has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Wave Life Sciences has efficiently used its assets last year compared to the US Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Wave Life Sciences improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Wave Life Sciences's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Wave Life Sciences has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

WVE Health

 How is Wave Life Sciences's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Wave Life Sciences's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Wave Life Sciences is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Wave Life Sciences's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Wave Life Sciences's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 9.1x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Wave Life Sciences Company Filings, last reported 1 month ago.

NasdaqGM:WVE Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 204.73 34.70 287.57
2018-12-31 81.22 0.00 174.82
2018-09-30 114.48 0.00 210.49
2018-06-30 147.17 0.00 241.43
2018-03-31 117.92 0.00 110.49
2017-12-31 147.48 0.02 142.50
2017-09-30 173.73 0.03 168.46
2017-06-30 196.79 0.05 197.39
2017-03-31 124.96 0.06 129.48
2016-12-31 142.74 0.08 150.29
2016-09-30 159.01 0.09 169.02
2016-06-30 174.15 0.11 181.77
2016-03-31 154.40 0.12 153.40
2015-12-31 161.37 0.14 161.22
2015-09-30 67.40 0.16 66.04
2015-06-30 8.96 0.17 7.78
2015-03-31 2.03 0.00 1.05
2014-12-31 2.03 0.00 1.05
2013-12-31 -7.76 9.60 0.44
  • Wave Life Sciences's level of debt (16.9%) compared to net worth is satisfactory (less than 40%).
  • Wave Life Sciences had negative shareholder equity 5 years ago, it is now positive therefore their debt level has improved.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Wave Life Sciences has sufficient cash runway for more than 3 years based on current free cash flow.
  • Wave Life Sciences has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 13.9% each year.
X
Financial health checks
We assess Wave Life Sciences's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Wave Life Sciences has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

WVE Dividends

 What is Wave Life Sciences's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Wave Life Sciences dividends.
If you bought $2,000 of Wave Life Sciences shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Wave Life Sciences's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Wave Life Sciences's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGM:WVE Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
United States of America Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 10 Stocks 2.8%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2005 Stocks 2.5%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGM:WVE Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Wave Life Sciences has not reported any payouts.
  • Unable to verify if Wave Life Sciences's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Wave Life Sciences's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Wave Life Sciences has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Wave Life Sciences's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Wave Life Sciences afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Wave Life Sciences has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

WVE Management

 What is the CEO of Wave Life Sciences's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Paul Bolno
COMPENSATION $5,839,966
AGE 44
TENURE AS CEO 5.4 years
CEO Bio

Dr. Paul B. Bolno, M.D., MBA has been the Chief Executive Officer and President of WAVE Life Sciences Ltd. since December 2013. Prior to joining WAVE, Dr. Bolno served at GlaxoSmithKline from 2009 to 2013 in various roles, including Vice President of Worldwide Business Development, Head of Asia BD & Investments, Head of Global Neuroscience BD, a Director of Glaxo Welcome Manufacturing, Pte. Ltd. in Singapore and Vice President of Business Development for the Oncology Business Unit, where he helped establish GlaxoSmithKline’s global oncology business and served as a Member of the Oncology Executive Team, Oncology Commercial Board and Cancer Research Executive Team. Prior to GlaxoSmithKline, he served as the Director of Research at Two River Group Holdings, LLC (alternate name Two River LLC) from 2004 to 2009. He has been a Director of Wave Life Sciences Ltd. since April 2014. Dr. Bolno was a resident in General Surgery at the University of Massachusetts and Hahnemann University Hospital. He was a general surgery resident and completed his Post Doctoral Research Fellowship in Cardiothoracic Surgery at Drexel University. His research focused on directing stem cells for cardiac repair as well as other modalities for treating heart failure including cardiac assist devices. His research has been presented at numerous national and international meetings. He received a B.A. from Emory University and an M.D. from Hahnemann University School of Medicine. Dr. Bolno also received an M.B.A from Drexel University with a concentration in Health Care and Biotechnology.

CEO Compensation
  • Paul's compensation has increased whilst company is loss making.
  • Paul's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Wave Life Sciences management team in years:

2.3
Average Tenure
49.5
Average Age
  • The tenure for the Wave Life Sciences management team is about average.
Management Team

Paul Bolno

TITLE
President
COMPENSATION
$6M
AGE
44
TENURE
5.4 yrs

Keith Regnante

TITLE
Chief Financial Officer
COMPENSATION
$2M
AGE
48
TENURE
2.8 yrs

Chris Francis

TITLE
Senior VP of Corporate Development & Head of Emerging Areas
COMPENSATION
$2M
AGE
40
TENURE
2.3 yrs

Chandra Vargeese

TITLE
Senior Vice President of Drug Discovery
COMPENSATION
$2M
AGE
57
TENURE
4.8 yrs

Mike Panzara

TITLE
Chief Medical Officer
COMPENSATION
$2M
AGE
51
TENURE
0.4 yrs

Kyle Moran

TITLE
Senior Vice President of Operations & Business Analytics
AGE
47
TENURE
2.3 yrs

Tushar Misra

TITLE
Senior Vice President of Technical Operations
TENURE
0.4 yrs

Linda Rockett

TITLE
General Counsel
TENURE
3 yrs

Clare Carmichael

TITLE
Chief Human Resources Officer
AGE
58

Takeshi Wada

TITLE
Scientific Advisor
COMPENSATION
$29K
AGE
56
TENURE
2.3 yrs
Board of Directors Tenure

Average tenure and age of the Wave Life Sciences board of directors in years:

5.1
Average Tenure
50
Average Age
  • The tenure for the Wave Life Sciences board of directors is about average.
Board of Directors

Christian Henry

TITLE
Chairperson
COMPENSATION
$295K
AGE
50
TENURE
1.6 yrs

Paul Bolno

TITLE
President
COMPENSATION
$6M
AGE
44
TENURE
5.1 yrs

Peter Kolchinsky

TITLE
Independent Director
COMPENSATION
$246K
AGE
41
TENURE
4.3 yrs

Greg Verdine

TITLE
Director
COMPENSATION
$387K
AGE
59
TENURE
5.8 yrs

Koji Miura

TITLE
Independent Director
COMPENSATION
$245K
AGE
68
TENURE
6.6 yrs

Ken Takanashi

TITLE
Independent Director
COMPENSATION
$246K
AGE
54
TENURE
6.8 yrs

Ad Rawcliffe

TITLE
Independent Director
COMPENSATION
$245K
AGE
46
TENURE
2.3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
14. Mar 19 Sell Kagoshima Development Company 04. Sep 18 08. Mar 19 -157,791 $52.25 $-7,483,052
28. Jan 19 Buy RA Capital Management, LLC Company 24. Jan 19 24. Jan 19 263,158 $38.00 $10,000,004
16. Nov 18 Sell Gregory Verdine Individual 14. Nov 18 14. Nov 18 -15,000 $39.52 $-582,849
X
Management checks
We assess Wave Life Sciences's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Wave Life Sciences has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

WVE News

Simply Wall St News

Wave Life Sciences (NASDAQ:WVE) Shareholders Booked A 86% Gain In The Last Three Years

Wave Life Sciences isn't a profitable company, so it is unlikely we'll see a strong correlation between its share price and its earnings per share (EPS). … In the last 3 years Wave Life Sciences saw its revenue grow at 104% per year. … While the compound gain of 23% per year over three years is pretty good, you might argue it doesn't fully reflect the strong revenue growth.

Simply Wall St -

Does Wave Life Sciences Ltd. (NASDAQ:WVE) Have A High Beta?

Every stock in the market is exposed to this volatility, which is linked to the fact that stocks prices are correlated in an efficient market. … Beta can be a useful tool to understand how much a stock is influenced by market risk (volatility). … A stock with a beta below one is either less volatile than the market, or more volatile but not corellated with the overall market.

Simply Wall St -

Wave Life Sciences Ltd. (NASDAQ:WVE): What Are The Future Prospects?

The most recent earnings update Wave Life Sciences Ltd.'s (NASDAQ:WVE) released in December 2018 … company earnings became less negative compared to the previous year's level … as a result of recent tailwinds

Simply Wall St -

Wave Life Sciences Ltd. (NASDAQ:WVE): Time For A Financial Health Check

(NASDAQ:WVE), which sports a zero-debt capital structure, to include debt in its capital structure is the reduced cost of capital. … Is financial flexibility worth the lower cost of capital … Debt capital generally has lower cost of capital compared to equity funding.

Simply Wall St -

Should You Worry About Wave Life Sciences Ltd.'s (NASDAQ:WVE) CEO Salary Level?

This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. … How Does Paul Bolno's Compensation Compare With Similar Sized Companies. … is worth US$1.2b, and total annual CEO compensation is US$3.2m.

Simply Wall St -

Read This Before Buying Wave Life Sciences Ltd (NASDAQ:WVE) Shares

So shareholders might well want to know whether insiders have been buying or selling shares in Wave Life Sciences Ltd (NASDAQ:WVE). … The Last 12 Months Of Insider Transactions At Wave Life Sciences. … That means that even when the share price was below the current price of US$46.83, an insider wanted to cash in some shares.

Simply Wall St -

Should You Be Concerned About Wave Life Sciences Ltd's (NASDAQ:WVE) Historical Volatility?

If you're interested in Wave Life Sciences Ltd (NASDAQ:WVE), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could impact your portfolio. … Modern finance theory considers volatility to be a measure of risk, and there are two main types of price volatility. … Some investors use beta as a measure of how much a certain stock is impacted by market risk (volatility).

Simply Wall St -

Wave Life Sciences Ltd (NASDAQ:WVE): Should The Recent Earnings Drop Worry You?

Today I will examine Wave Life Sciences Ltd's (NASDAQ:WVE) latest earnings update (31 March 2018) and compare these figures against its performance over the past couple of years, in addition to how the rest of WVE's industry performed. … See our latest analysis for Wave Life Sciences? … WVE is loss-making, with the most recent trailing twelve-month earnings of -US$116.18m (from 31 March 2018), which compared to last year has become

Simply Wall St -

WVE Company Info

Description

Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces of novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. The company is primarily developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins. It focuses on proprietary programs in neurology in the central nervous system and neuromuscular system. The company has a research, license, and option agreement with Pfizer Inc. and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of stereopure oligonucleotide therapeutics and oligonucleotide therapeutics. Wave Life Sciences Ltd. was founded in 2012 and is based in Singapore.

Details
Name: Wave Life Sciences Ltd.
WVE
Exchange: NasdaqGM
Founded: 2012
$828,754,044
34,260,192
Website: http://www.wavelifesciences.com
Address: Wave Life Sciences Ltd.
Marina One East Tower,
No. 12-00, 7 Straits View,
Singapore,
018936,
Singapore
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM WVE Ordinary Shares Nasdaq Global Market US USD 11. Nov 2015
DB 1U5 Ordinary Shares Deutsche Boerse AG DE EUR 11. Nov 2015
Number of employees
Current staff
Staff numbers
250
Wave Life Sciences employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/05/24 00:43
End of day share price update: 2019/05/23 00:00
Last estimates confirmation: 2019/05/17
Last earnings filing: 2019/05/10
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.